ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/26/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

ALXN stock is up 6% since Alexion Pharmaceuticals (NASDAQ:ALXN) announced its third-quarter results on Wednesday, which saw a 23% year-over-year rise in revenue to $1.26 billion USD. ALXN Stock Outperforming Industry Alexion reported Q3 earnings of $2.79 per share, which is a 38% increa...

Are you worried about healthcare-sector stocks? Considering their performance lately, some nervousness is understandable. The S&P 500 index has climbed 9.8% higher over the past twelve months, but the iShares U.S. Healthcare ETF rose just 0.4% over the same period. Shares of health-rel...

Alexion Pharmaceuticals ( ALXN ) announced that it would acquire Achillion Pharmaceuticals ( ACHN ) for approximately $930 million. There are other stipulations that were added to make this deal decent for Achillion. There are still some measures that must be closed before such a deal can ...

Alexion Pharmaceuticals Inc (ALXN) Q3 2019 Results Earnings Conference Call October 23, 2019 08:00 A.M. ET Company Participants Susan Altschuller - Vice President, Investor Relations Ludwig Hantson - CEO Paul Clancy - Chief Financial Officer John Orloff - Global Head of R&...

Image source: The Motley Fool. Alexion Pharmaceuticals Inc   (NASDAQ: ALXN) Q3 2019 Earnings Call Oct 23, 2019 , 8:00 a.m. ET Operator Continue reading

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Alexion Pharmaceuticals ( ALXN ) Q3 results : Revenues: $1,263.1M (+23.0%); Soliris: $990.5M (+11.5%); Ultomiris: $89.9M (-99.4%); Strensiq: $154.3M (+36.3%); Kanuma: $28.4M (+12.3%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks...

Alexion Pharmaceuticals (NASDAQ: ALXN ): Non-GAAP EPS of $2.79 beats by $0.31 ; GAAP EPS of $2.08 beats by $0.13 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase 3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79 Received 2 recent regulatory approvals - ULTOMIRIS ® (ravulizumab-cwvz) for atypical hemolytic uremic ...